Related references
Note: Only part of the references are listed.The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus
R. A. Hickman et al.
CLINICAL RHEUMATOLOGY (2015)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
Ellen M. Ginzler et al.
JOURNAL OF RHEUMATOLOGY (2014)
Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
Robert Zimmer et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
Marie B. Condon et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
Eduardo F. Mysler et al.
ARTHRITIS AND RHEUMATISM (2013)
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)
M. Witt et al.
LUPUS (2013)
Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis
R. J. Davies et al.
LUPUS (2013)
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
Daniel J. Wallace et al.
RHEUMATOLOGY (2013)
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
L. Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts
Candido Diaz-Lagares et al.
AUTOIMMUNITY REVIEWS (2012)
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
A. Fernandez-Nebro et al.
LUPUS (2012)
Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen
Amara N. Ezeonyeji et al.
RHEUMATOLOGY (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
Ellen M. Ginzler et al.
ARTHRITIS RESEARCH & THERAPY (2012)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus
L. F. Pinto et al.
LUPUS (2011)
Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy
Dario Roccatello et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Measures of Adult Systemic Lupus Erythematosus Updated Version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)
Juanita Romero-Diaz et al.
ARTHRITIS CARE & RESEARCH (2011)
The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
J. T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Safety and Efficacy of Rituximab in Systemic Lupus Erythematosus
Benjamin Terrier et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients
M. Garcia-Carrasco et al.
LUPUS (2010)
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
Daniel J. Wallace et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard A. Furie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years)
Raashid Luqmani et al.
RHEUMATOLOGY (2009)
B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus
A. Podolskaya et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2008)
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2008)
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Treatment of refractory SLE with rituximab plus cyclophosphamide:: clinical effects, serological changes, and predictors of response
T. Jonsdottir et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
Mikiko Tokunaga et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
The American college of rheumatology response criteria for systemic lupus erythematosus clinical trials - Measures of overall disease activity
MH Liang
ARTHRITIS AND RHEUMATISM (2004)
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154 - A randomized, double-blind, placebo-controlled trial
KC Kalunian et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
